Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Head-to-head comparison of Cortagen and Livagen — mechanism, side effects, legal status, and pricing.
A short synthetic peptide bioregulator (Ala-Glu-Asp-Pro) from the Khavinson 'Cytomax/Cytogen' family, marketed for cartilage and connective-tissue support. Evidence is largely Russian-language and preclinical.
Livagen is a synthetic tetrapeptide (Lys-Glu-Asp-Ala / KEDA) from the Khavinson short-peptide 'bioregulator' series, developed at the St. Petersburg Institute of Bioregulation and Gerontology. Marketed in Russia primarily as a food-supplement-grade cytomax; not FDA-approved in the US; research-use only.
Cortagen
Livagen
Category
Legal Status
Mechanism
Side Effects
Contraindications
COA-verified vendors · trust score ≥70 required · single-vial price — bulk/bundle deals may be lower
Cortagen
Livagen
COA corpus from Disclosed Labs — independently tested batches only.
Cortagen
9
COAs
99.6%
Avg purity
4
Labs
Livagen
9
COAs
99.6%
Avg purity
5
Labs
Primarily Russian institutional studies; no large independent controlled human trials.
Evidence base is essentially single-lab (Khavinson, Lezhava, and collaborators). In vitro studies on lymphocyte chromatin in elderly subjects and small Russian reports in chronic gastritis and immune senescence. No FDA-registered clinical trials and no Western RCTs.
Key references
Cortagen (Recovery) and Livagen (Immune) are in different categories and target different biological pathways. This is a common pattern in multi-compound research protocols. Researchers should monitor the biomarkers from both profiles and watch for interactions listed in each compound’s contraindications. Consult a licensed healthcare provider before combining any research compounds.
This platform provides informational tools only, not medical advice. This comparison is for educational purposes only. Consult a licensed provider.
Lab Testing